Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 6.99 CHF 4.33% Market Closed
Market Cap: 139.5m CHF

Net Margin
Newron Pharmaceuticals SpA

30.8%
Current
-198%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.8%
=
Net Income
15.8m
/
Revenue
51.4m

Net Margin Across Competitors

Newron Pharmaceuticals SpA
Glance View

Market Cap
139.5m CHF
Industry
Pharmaceuticals

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

NWRN Intrinsic Value
10.89 CHF
Undervaluation 36%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
30.8%
=
Net Income
15.8m
/
Revenue
51.4m
What is the Net Margin of Newron Pharmaceuticals SpA?

Based on Newron Pharmaceuticals SpA's most recent financial statements, the company has Net Margin of 30.8%.

Back to Top